Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Bryan K. Sorensen, Antioch US

Bryan K. Sorensen, Antioch, IL US

Patent application numberDescriptionPublished
20090054426TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.02-26-2009
20090176783INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.07-09-2009
20090192141METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.07-30-2009
20090192198INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.07-30-2009
20090253723PROTEIN KINASE INHIBITORS - Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.10-08-2009
20100152179TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.06-17-2010
20100222316INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.09-02-2010
20100305118PYRIMIDINE INHIBITORS OF KINASE ACTIVITY - Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof,12-02-2010
20100305126Pyrimidine Inhibitors of Kinase Activity - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof,12-02-2010
20110124632IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION - Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.05-26-2011

Patent applications by Bryan K. Sorensen, Antioch, IL US